Horizon Therapeutics plc

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

Plus: Danilkowicz to lead commercial at Alumis and an update from Precision

Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more

BioCentury’s analysis of 12 months of dealmaking between biotechs and top pharmas

With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way

Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more

Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney

The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients

The U.S. preeminence in life sciences at risk

Plus: Amgen Horizon deal closes and updates from Exscientia, Scleroderma Research Foundation, 7wireVentures and Orakl